Last reviewed · How we verify
NCT03491956
Double Filtration Plasmapheresis (DFPP) and Lipid Metabolism
NA trial testing DFPP in DFPP and Platelet Function in 30 participants. Status unknown.
1 April 2021
Quick facts
| Lead sponsor | Shanghai Pudong Hospital |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 1 February 2018 |
| Primary completion | 1 April 2021 |
| Estimated completion | 1 April 2021 |
| Sites | 1 location across China |
Drugs / interventions tested
- DFPP
Conditions studied
- DFPP and Platelet Function — all drugs for DFPP and Platelet Function →
Sponsor
Shanghai Pudong Hospital
Who can join
Adults 18 to 80, any sex, with DFPP and Platelet Function. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Little clinic trials showed that Double Filtration Plasmapheresis (DFPP) could improve lipid metabolism, however, whether DFPP can improve platelet function and recover Endothelial function is unknown. In this study, we try to confirm the hypothesis that DFPP can improve endothelial function in hyperlipidemia patients.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Plasma Purification Treatment Relieves the Damage of Hyperlipidemia to PBMCs.
Zhang XM, Gu YH, Deng H, Xu ZQ, et al · · 2021 · cited 4× · PMID 34307504 · DOI 10.3389/fcvm.2021.691336 -
Plasma purification is associated with reduced inflammation factors and down-regulation of lipid metabolic and ER stress proteins in patients with hyperlipidemia
Zhang XM, Gu YH, Deng H, Xu ZQ, et al · · 2020 · DOI 10.21203/rs.3.rs-70758/v3
Verify or expand the search:
- PubMed search for NCT03491956
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of DFPP
Trials testing the same drug.
- NCT06224296 — The Exploratory Study About the Effect of Using Double Filtration Plasmapheresis (DFPP) Removing Inflammatory Cytokines, · NA · unknown
Other Shanghai Pudong Hospital trials
Trials by the same sponsor.
- NCT07106034 — Standard Second-line Therapy With ONgericimab and TOripalimab in pMMR/MSS Colorectal Cancer: a Single-arm Phase II Trial · Phase 2 · not yet recruiting
- NCT06501183 — Anti-CDH17 CAR-T Cell Injection in Patients With CDH17-positive Advanced Malignant Solid Tumors · Phase 1 · recruiting
- NCT05559177 — An Open, Dose-escalation Clinical Study of Chimeric Exosomal Tumor Vaccines for Recurrent or Metastatic Bladder Cancer · EARLY_PHASE1 · unknown
- NCT05473884 — Lesion Preparation in Femoropopliteal Artery Occlusion Disease · unknown
- NCT05374772 — A Retrospective Study in Patients With Mild to Moderate COVID-19 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03491956 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Pudong Hospital
- Last refreshed: 17 March 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03491956.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing